Tag Archives: ADAP

SunTrust Robinson Reiterates Their Buy Rating on Adaptimmune Therapeutics

In a report released today, Peter Lawson from SunTrust Robinson reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP), with a price target of $10. The company’s shares closed yesterday at $8.10. According to TipRanks.com, Lawson is a 4-star analyst

SunTrust Robinson Reiterates a Buy Rating on Adaptimmune Therapeutics

SunTrust Robinson analyst Peter Lawson reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) on October 9 and set a price target of $10. The company’s shares opened today at $7.88. According to TipRanks.com, Lawson is a 5-star analyst with

Adaptimmune Therapeutics Receives a New Rating from Top Analyst

Cowen & Co. analyst Eric Schmidt reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) today. The company’s shares opened today at $5.21. Schmidt observed: “Adaptimmune reported updated data from its Phase II trial of NY-ESO SPEAR T cells.” According

Leerink Swann Thinks Adaptimmune Therapeutics’ Stock is Going to Recover

Leerink Swann analyst Michael Schmidt reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP) today and set a price target of $15. The company’s shares opened today at $4.98, close to its 52-week low of $3.76. Schmidt observed: “We are

Adaptimmune Therapeutics Receives a Buy from Cowen & Co.

In a report released today, Eric Schmidt from Cowen & Co. reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP). The company’s shares opened today at $5.41. Schmidt wrote: “Adaptimmune reported a Q3 net loss of $18MM and a September

Leerink Swann Reiterates a Buy Rating on Adaptimmune Therapeutics

According to The Fly, in a report released yesterday, Michael Schmidt from Leerink Swann reiterated a Buy rating on Adaptimmune Therapeutics (NASDAQ: ADAP). The company’s shares opened today at $10.11.Schmidt observed, “We are reiterating our Outperform rating on ADAP shares